U.S. markets close in 3 hours 6 minutes

DURECT Corporation (DRRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
1.6800-0.0600 (-3.45%)
As of 12:48PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close1.7400
Open1.7500
Bid1.6800 x 1800
Ask1.6900 x 1300
Day's Range1.6620 - 1.7800
52 Week Range1.5200 - 2.9600
Volume604,373
Avg. Volume2,317,750
Market Cap381.699M
Beta (5Y Monthly)1.44
PE Ratio (TTM)N/A
EPS (TTM)-0.0030
Earnings DateMar 04, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • DURECT Corporation Announces Publication of DUR-928's Mechanism of Action
    PR Newswire

    DURECT Corporation Announces Publication of DUR-928's Mechanism of Action

    DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed research paper describing the binding sites and proposed mechanism of action of its lead drug candidate, an endogenous sulfated oxysterol and epigenetic regulator, DUR-928, in The Journal of Lipid Research.

  • Benzinga

    Durect: Q4 Earnings Insights

    Shares of Durect (NASDAQ:DRRX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 100.00% year over year to ($0.04), which missed the estimate of ($0.03). Revenue of $2,207,000 declined by 79.34% year over year, which missed the estimate of $6,570,000. Guidance Durect hasn't issued any earnings guidance for the time being. Revenue guidance hasn't been issued by the company for now. Conference Call Details Date: Mar 04, 2021 View more earnings on DRRX Time: 04:30 PM ET Webcast URL: http://public.viavid.com/player/index.php?id=143367 Technicals Company's 52-week high was at $2.96 Company's 52-week low was at $0.95 Price action over last quarter: Up 24.85% Company Profile Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, Remoxy, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the United States. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For March 4, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
    Zacks

    Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates

    Durect (DRRX) delivered earnings and revenue surprises of -33.33% and -66.91%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?